Ulcerative Colitis

Plevy, will describe results suggesting that oral administration of Guanilib ameliorates inflammation in a mouse model of experimental colitis, presumably via downregulation of the key cytokines, such as tumor necrosis factor, that are known to be involved in the causes of IBD.

For more information on the conference, visit http://www.ddw.org.

Dr.

Scott Plevy, Associate Professor of Medicine and Immunology and the Co-Director of the Inflammatory Bowel Disease Center at the University of Pittsburg Medical Center, Pittsburg, PA is a principle collaborator on Callisto's Guanilib research program.

"We are very encouraged by the Guanilib data from Dr.

Plevy's laboratory, and pleased to have this new research presented to leading research professionals in the field," said Callisto CEO Dr.

Gary S.

Jacob.

"Dr.

Plevy and his group were the first to demonstrate that Guanilib inhibits gastrointestinal inflammation in an animal model of colitis, and now are providing insight into just how Guanilib exerts its antiinflammatory activity.

Their research supports our commitment to pursue development of Guanilib as a completely new approach to the treatment of gastrointestinal disease." One of the major physiological funct...

"Think about it: nothing makes you feel worse than nausea and digestive issues, so people are certainly willing to pay for this.

And it's all patented."Shares of Salix Pharmaceuticals rose 8 cents on Tuesday to $15.53.

Copyright ©2006 MarketWatch, Inc.

All rights reserved.

Please see our Terms of Use.

MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc." Return to top of page Just Released!

— A Rising Tide for Global Equities By Fisher Investments The seemingly tired, old bull market advanced in the fourth quarter as strong fundamentals outweighed unenthusiastic sentiment.

For the year, global equities bested alternatives like...

F...

* Obesity and inactivity: Being overweight, especially around the waist, and a sedentary lifestyle.

* Smoking: Smokers are 30 to 40 percent more likely than nonsmokers to die from colorectal cancer.

Screening for polyps and cancer before they can cause symptoms is by far the best way to prevent or treat colorectal cancer.

Everyone age 50 and older should be screened, or younger if you have high risk for the disease.

Talk to your doctor about which test is right for you.

The recommended screening options include: * Stool screening: Known as fecal occult blood tests, these are simple home screening tests that check for hidden blood in your stool.

Inexpensive ($10 to $30) and much improved, they should be taken annually.

Another successful home testing kit is the new fecal immunochemical test.

Ask your doctor about these different options.

* Double-contrast barium enema: This procedure involves several X- rays of the entire colon and rectum but first requires a rather unpleasant enema with barium solution and air, which is pumped into the rectum.

This is solely a diagnostic procedure, done without sedation and costs $200 to $400.

* Sigmoidoscopy: A flexible tube with a light and camera on the end is inserted into the rectum and lower third of the colon.

If identified, polyps can be removed at the same time and biopsied.

This procedure is usually done without se...